Latest Headlines

  1. HKeyBio Debuts HKEY-ExE™ 1.0 To Address Preclinical Bottlenecks In EoE And EgE Drug Developmen 6/24/2026

    HKeyBio, a preclinical contract research organization focused on autoimmune and allergic diseases, today announced the launch of HKEY-ExE™ 1.0, an EoE&EgE Evaluation Framework for eosinophilic esophagitis (EoE), eosinophilic gastroenteritis (EgE, also referred to as EGE), and related eosinophilic gastrointestinal disorders (EGIDs).

  2. Antares Therapeutics Enters Agreement With Novartis To Discover, Develop And Commercialize First-In-Class Cancer Therapies 6/24/2026

    Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop and commercialize small molecule therapies against promising but historically undruggable oncology targets.

  3. Imbria Pharmaceuticals Receives FDA Orphan Drug Designation For Ninerafaxstat For Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy 6/24/2026

    Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ninerafaxstat for the treatment of symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

  4. Simulations Plus Advances Agentic Drug Development With NVIDIA BioNeMo Agent Toolkit 6/23/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit.

  5. HighRes And Waters Collaborate To Advance Drug Discovery Through Robotic Automation 6/23/2026

    HighRes today announced a strategic collaboration to enable robotic capabilities on Waters Biosciences, formerly BD Biosciences, flow cytometers to automate key experimental steps and streamline research workflows, from basic research to drug discovery.

  6. SandboxAQ Launches Virtual Screening Solution For GPCR Drug Discovery, Accelerated By NVIDIA BioNeMo 6/23/2026

    SandboxAQ today announced a new virtual screening solution that helps drug developers identify promising candidates faster and at lower cost for G protein-coupled receptors (GPCRs), one of the most valuable yet hardest-to-drug families of targets.

  7. BioMendics Receives FDA Fast Track Designation For BM-3103 (TolaSure Gel) For Epidermolysis Bullosa Simplex 6/23/2026

    BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BM-3103, formulated as TolaSure Gel, for the treatment of Epidermolysis Bullosa Simplex (EBS).

  8. Abbisko Therapeutics Deepens R&D Collaboration With Lilly 6/23/2026

    Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company.

  9. Genialis Launches BioBridge To Help Derisk Global Drug Development Of China-Origin Oncology Drugs 6/22/2026

    Genialis, the therapeutic intelligence company, today announced Genialis BioBridge to help pharmaceutical sponsors translate clinical results generated in Chinese patient populations into biomarker-ready assets for Western trials and regulatory submissions.

  10. Bayer And Iambic Collaborate To Advance Drug Discovery With AI 6/22/2026

    Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic’s AI-driven platform.